← Crispr Therapeutics overview

Crispr Therapeutics vs Gilead Sciences: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Crispr Therapeutics AG (CRSP)

Q3 2026
▲3▼1

CRISPR Q3: Casgevy pediatric approval, revenue jump, pipeline catalysts

  • Casgevy FDA approval for young children Casgevy won FDA approval for children as young as two, expanding the eligible U.S. patient pool by about 5,500 and opening a potential $12.1 billion market. This directly boosts future revenue prospects.

    This is a major new approval that expands the market and is a key positive driver for the stock.

  • Q2 revenue surge and strong cash position Q2 revenue jumped 78% sequentially to $76 million, net loss narrowed, and $2.36 billion in cash funds years of operations. This shows improving financial health and reduces near-term funding risk.

    Financial results are a key driver of investor sentiment and stock price.

  • Pipeline catalysts and competitive win Upcoming data for CTX310 (cholesterol) and CTX611 (clot therapy), plus off-the-shelf CAR-T, could drive value. Novartis's pelacarsen failure may boost CRSP's CTX321, and Ken Fisher opened a small stake.

    Pipeline progress and competitive dynamics are important for future growth prospects.

  • Adoption challenges and valuation uncertainty Casgevy adoption is slow due to complex procedures, revenue is still tiny against continuing losses, CTX321's advantage is only animal-tested, and valuation is highly assumption-dependent. Analyst targets average $86.21, below one model's $221.98 fair value.

    These risks could limit upside and are important counterweights to the positive drivers.

August 2026
▲3

Casgevy sales jump, FDA widens label, and a rival's failure lifts CRSP's pipeline hopes

  • Casgevy revenue accelerates and FDA widens the label Q2 Casgevy revenue hit $76 million, up 78% from the prior quarter and 151% from a year ago, and the FDA approved it for children as young as 2, adding roughly 5,500 eligible patients. Net loss narrowed to $91.2 million from $208.5 million, with $2.36 billion in cash. Real sales and a bigger market make the gene-editing story less speculative, supporting the stock.

    This is the clearest new fundamental proof that CRSP's only approved product is selling and its market is expanding.

  • Novartis heart-drug failure may push CRSP's next-gen program forward Novartis's pelacarsen failed its Phase 3 heart trial despite lowering Lp(a), a rival approach. Citi says this makes CRSP more likely to prioritize its more potent next-generation CTX321 Lp(a) candidate, and kept a Buy rating and $88 target. Less competition and a clearer pipeline focus help the stock, though CTX321's advantage is only shown in animals so far.

    A competitor's failure directly changes CRSP's pipeline priorities and analyst view, a new force on the stock.

  • Ken Fisher's fund discloses a new CRSP stake Billionaire Ken Fisher's Fisher Asset Management opened a new position of 77,960 CRISPR Therapeutics shares worth about $4.25 million as of June 30, per 13F filings. A well-known investor buying in can draw attention and fresh demand to a beaten-down stock, though the position is small relative to CRSP's size.

    A new institutional buyer is a fresh, concrete signal of outside money coming into the stock.

  • Valuation debate: cheap on cash-flow models, fair on book value One model pegs fair value at $221.98, implying the stock is deeply undervalued, while analyst targets average $86.21 and price-to-book sits near the industry average. CRSP still loses money on tiny revenue, so whether it is cheap depends entirely on assumptions about future Casgevy and pipeline sales. That uncertainty cuts both ways.

    It frames the central bull-bear tension behind the stock's price without repeating any single event.

Latest
▲3

Casgevy sales jump, FDA widens label, and a rival's failure lifts CRSP's pipeline hopes

  • Casgevy revenue accelerates and FDA widens the label Q2 Casgevy revenue hit $76 million, up 78% from the prior quarter and 151% from a year ago, and the FDA approved it for children as young as 2, adding roughly 5,500 eligible patients. Net loss narrowed to $91.2 million from $208.5 million, with $2.36 billion in cash. Real sales and a bigger market make the gene-editing story less speculative, supporting the stock.

    This is the clearest new fundamental proof that CRSP's only approved product is selling and its market is expanding.

  • Novartis heart-drug failure may push CRSP's next-gen program forward Novartis's pelacarsen failed its Phase 3 heart trial despite lowering Lp(a), a rival approach. Citi says this makes CRSP more likely to prioritize its more potent next-generation CTX321 Lp(a) candidate, and kept a Buy rating and $88 target. Less competition and a clearer pipeline focus help the stock, though CTX321's advantage is only shown in animals so far.

    A competitor's failure directly changes CRSP's pipeline priorities and analyst view, a new force on the stock.

  • Ken Fisher's fund discloses a new CRSP stake Billionaire Ken Fisher's Fisher Asset Management opened a new position of 77,960 CRISPR Therapeutics shares worth about $4.25 million as of June 30, per 13F filings. A well-known investor buying in can draw attention and fresh demand to a beaten-down stock, though the position is small relative to CRSP's size.

    A new institutional buyer is a fresh, concrete signal of outside money coming into the stock.

  • Valuation debate: cheap on cash-flow models, fair on book value One model pegs fair value at $221.98, implying the stock is deeply undervalued, while analyst targets average $86.21 and price-to-book sits near the industry average. CRSP still loses money on tiny revenue, so whether it is cheap depends entirely on assumptions about future Casgevy and pipeline sales. That uncertainty cuts both ways.

    It frames the central bull-bear tension behind the stock's price without repeating any single event.

July 2026
▲3

Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story

  • Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.

    This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.

  • New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.

    It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.

  • Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.

    These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.

  • Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.

    This is the main counterweight: the company is still far from profitable, which limits near-term upside.

▲3

Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story

  • Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.

    This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.

  • New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.

    It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.

  • Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.

    These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.

  • Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.

    This is the main counterweight: the company is still far from profitable, which limits near-term upside.

Gilead Sciences Inc (GILD)

Q3 2026
▲2▼1

Gilead Q3: strong HIV sales and raised guidance offset by huge acquisition losses

  • Q2 beat and guidance raised twice Gilead's Q2 revenue beat at $7.8B, up 10%, and management raised full-year guidance twice to $30.1–30.4B. The dividend also rose 3.8%, signaling confidence in the business.

    This is the core new financial result and outlook that drove the stock this quarter.

  • HIV franchise strength and new approvals HIV sales rose 12% to $5.7B, with Yeztugo surging and Bixlenvo approved. A once-weekly oral HIV regimen advanced, and a legal win blocked illegal Biktarvy imports, protecting the franchise.

    HIV is Gilead's biggest business, and these new gains are central to the quarter's positive momentum.

  • Massive acquisition charges and cash drain Gilead took $11.2B in acquired IPR&D charges from Arcellx, Tubulis, and Ouro, causing large GAAP and non-GAAP losses and cutting cash from $10.6B to $3.2B. This is a real financial counterweight.

    These charges and the cash decline are the main negative force that weighed on the stock this quarter.

  • Pipeline progress but early-stage and pricing unclear Pipeline wins included Trodelvy's EU expansion and anito-cel, but these remain early-stage with no near-term revenue. Lenacapavir access pricing is still unclear, leaving uncertainty about future profits.

    This captures the mixed nature of pipeline advances that are promising but not yet contributing revenue.

August 2026
▲2▼1

Gilead's Q2 Beat, Raised Guidance, New Launches Offset Big Acquisition Costs

  • Q2 beat and raised guidance Gilead's second-quarter revenue beat expectations at $7.8 billion, up 10%, and management raised full-year guidance twice to $30.1–$30.4 billion. The dividend also rose 3.8%, signaling confidence in the business.

    This is the core financial result that drove positive sentiment during the period.

  • HIV franchise strength and new launches HIV sales climbed 12% to $5.7 billion, PrEP topped $1 billion quarterly, and Yeztugo jumped to $232 million from $15 million. Bixlenvo won FDA approval, Trodelvy expanded in the EU, and lenacapavir licensing widened.

    These are the key operational drivers showing growth beyond the core HIV business.

  • Large acquisition charges hit earnings and cash Gilead took $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines, causing large GAAP and non-GAAP losses and cutting cash from $10.6 billion to $3.2 billion. This is a real cost of future growth, though not an operating cash drain.

    This is the main counterweight that pressured reported results and the balance sheet.

  • Pipeline wins are early-stage Positive pipeline news, such as the once-weekly oral HIV regimen and new drug launches, remains early and not yet contributing near-term revenue. Investors weigh future potential against current costs.

    This explains why pipeline progress is not yet a near-term earnings driver, balancing optimism.

Latest
▲3

Gilead lifts 2026 outlook and dividend as HIV sales surge

  • Raised 2026 sales outlook and dividend hike Gilead raised its 2026 product sales outlook to $30.1–$30.4 billion and lifted its quarterly dividend 3.8%. Stronger guidance tells investors the HIV business is performing better than expected, which supports the stock price.

    This is the period's biggest new event and directly answers what is driving GILD now.

  • HIV franchise sales accelerate Quarterly HIV sales rose 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy up 48%. Yeztugo, the twice-yearly prevention shot, jumped to $232 million from $15 million a year earlier, showing the new product is taking off.

    HIV is Gilead's core profit engine, and its growth is the fundamental force behind the raised guidance.

  • Big acquisition charges create reported losses Gilead recorded $11.2 billion in acquired research charges from buying Arcellx, Tubulis and Ouro Medicines, causing large accounting losses and cutting cash to $3.2 billion from $10.6 billion. This is a real cost of building future growth, but it does not reflect day-to-day operations.

    It is the main counterweight to the good news and explains why reported earnings look weak despite strong sales.

  • New lenacapavir licensing and FDA approval widen reach Gilead expanded royalty-free lenacapavir licensing to a once-yearly HIV prevention shot across 120 lower-income countries, and won FDA approval for Bixlenvo, a small once-daily HIV pill. Both broaden the HIV portfolio and add future sales.

    These regulatory and access moves extend Gilead's HIV leadership, a key long-term driver.

September 2026
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

  • HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

    This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

  • FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

    A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

  • European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

    A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

  • Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

    New pipeline additions signal longer-term growth potential, which can support a higher valuation.

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

  • Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

    This is the period's central event and directly explains the positive fundamental momentum behind GILD.

  • PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

    It highlights a key new growth driver that is boosting investor confidence and future sales.

  • Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

    It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

  • Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

    It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 2026
▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.